Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
54.3M
-
Shares change
-
-1.09M
-
Total reported value, excl. options
-
$81M
-
Value change
-
-$2.24M
-
Put/Call ratio
-
0.08
-
Number of buys
-
22
-
Number of sells
-
-40
-
Price
-
$1.49
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2022
88 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q1 2022.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.3M shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (17.3M shares), PURA VIDA INVESTMENTS, LLC (12.2M shares), BlackRock Inc. (4.93M shares), VANGUARD GROUP INC (3.99M shares), ORBIMED ADVISORS LLC (3.49M shares), Defender Capital, LLC. (2.56M shares), STATE STREET CORP (1.36M shares), GEODE CAPITAL MANAGEMENT, LLC (1.27M shares), Nuveen Asset Management, LLC (1.03M shares), and Schonfeld Strategic Advisors LLC (1.01M shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.